TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8868017
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate regimen
Study: 8868017
Drug: Intramuscular magnesium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular magnesium sulfate regimen
Study: 1299709
Drug: Regimen A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A, standard dosage of clofazimine (CLO) in multidrug therapy (MDT) regimen
Study: 1299709
Drug: Regimen B,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B, CLO 600 mg once every 4 weeks
Study: 1299709
Drug: Regimen C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C, CLO 1200 mg once every 4 weeks
Study: 6608419
Drug: Potassium cardioplegic
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium cardioplegic solutions with added blood (group B)
Study: 30628813
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg for five days)
Study: 26391511
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy with weekly mobile phone messages for three months
Study: 18336488
Drug: Intensive drug
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive drug administration teaching using an online module and high fidelity simulation
Study: 10699339
Drug: Trivalent cold-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent cold-adapted influenza vaccine
Study: 9200764
Drug: Levomepromazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomepromazine (50 mg/day)
Study: 9200764
Drug: Thioridazine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (50 mg/day)
Study: 3882371
Drug: New device
Approvals — FDA: no, EMA: no, PMDA: no
Description: New device for giving multiple injections of short‐acting insulin
Study: 3882371
Drug: Conventional syringes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional syringes for injections of short‐acting insulin
Study: 27468542
Drug: Qingxue Dan
Normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingxue Dan (QXD) 900 mg/d for 8 weeks
Study: 24509284
Drug: Hypothermia induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia induced by rapid infusion of 600 to 2,000 ml cold saline and endovascular cooling
Study: 17556425
Drug: 2 l
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l fill of dialysate
Study: 17556425
Drug: 3 l
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 l fill of dialysate
Study: 11942049
Drug: Intermittent maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent maintenance chemotherapy
Study: 9467547
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg cyclic
Study: 9467547
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily and cyclic
Study: 2529410
Drug: Ethanol solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol solution (0.5 g ethanol/kg B.Wt.)
Study: 676644
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) until ET(CO2) < 8% (group I)
Study: 676644
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) until ET(CO2) < 6.5% (group II)
Study: 676644
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) + additional intramuscular naloxone (group III)
Study: 676644
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (0.04 mg increments every 3 min) + additional intramuscular naloxone (group IV)
Study: 21244446
Drug: Intra‐articular 70%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐articular 70% ethyl alcohol in combination with 2 percutaneously placed transarticular lag screws (EA‐TLS)
Study: 19178123
Drug: Subcutaneous interferon-beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interferon-beta-1a (SC IFNb1a) administered three times a week
Study: 19178123
Drug: Intramuscular interferon-beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular interferon-beta-1a (IM IFNb1a) administered once a week
Study: 19178123
Drug: Subcutaneous interferon-beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interferon-beta-1a (SC IFNb1a)
Study: 19178123
Drug: Intramuscular interferon-beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular interferon-beta-1a (IM IFNb1a)
Study: 17705694
Drug: Rosiglitazone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (1 year administration)
Study: 21777702
Drug: Polypill containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill containing 75 mg aspirin, 40 mg simvastatin, 10 mg lisinopril, and either 12.5 mg hydrochlorothiazide or 50 mg atenolol
Study: 19396428
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (surgical release of the internal obturator tendon)
Study: 19396428
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-operative treatment)
Study: 12823077
Drug: Fluvoxamine CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine CR (100 to 300 mg once daily for 12 weeks)
Study: 7784236
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (digitalis, diuretics, and vasodilators) for 8.1 +/- 0.7 months (Control)
Study: 7784236
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus prednisone and azathioprine
Study: 7784236
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus prednisone and cyclosporine
Study: 28662153
Drug: Daily physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physiotherapy with progressive knee‐extension strength training (10RM), 3 x 10 repetitions, of the fractured limb using ankle weight cuffs.
Study: 28662153
Drug: Daily physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physiotherapy without strength training.
Study: 25844612
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2%/BP 3.75% gel
Study: 23586591
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% cream for 4 weeks after non-surgical nail ablation with urea 40% paste
Study: 16881474
Drug: transrectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transrectal lidocaine gel
Study: 16881474
Drug: quadrant lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quadrant lidocaine injections
Study: 16881474
Drug: apex‐only lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: apex‐only lidocaine injections
Study: 25139979
Drug: Parenteral cysteine-HCl
Normalized name: Cysteine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cysteine-HCl (CYS group) at 121 mg/kg/d for ≥7 days
Study: 21712498
Drug: darunavir/ritonavir (600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir (600/100 mg twice daily)
Study: 21712498
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of darunavir/ritonavir and rosuvastatin
Study: 18279940
Drug: Intermittent Androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Androgen Deprivation (IAD) therapy with bicalutamide 150 mg once daily in on-phases and no therapy in off-phases (Group A)
Study: 18279940
Drug: Intermittent Androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Androgen Deprivation (IAD) therapy with bicalutamide 150 mg once daily in on-phases and etoricoxib 60 mg once daily in off-phases (Group B)
Study: 11776031
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide 300 mg/m2, vincristine 1.4 mg/m2, adriamycin 50 mg/m2, lomustine 50 mg/m2 on day 1, and cisplatin 20 mg/m2 on days 1-5, repeated every 4-6 weeks for 4 cycles, followed by oral ftorafur (FT-207) 600-900 mg/d for 1 year
Study: 11776031
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cyclophosphamide, vincristine, adriamycin, lomustine, and cisplatin
Study: 8858224
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (serum free insulin approximately 480 pmol/l)
Study: 8858224
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (physiological NaCl solution)
Study: 8858224
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of insulin infusion vs saline infusion
Study: 1634647
Drug: Nicoderm (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicoderm (nicotine transdermal system) 14 mg/day applied to upper back
Study: 1634647
Drug: Nicoderm (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicoderm (nicotine transdermal system) 14 mg/day applied to upper outer arm
Study: 1634647
Drug: Nicoderm (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicoderm (nicotine transdermal system) 14 mg/day applied to upper chest
Study: 24973281
Drug: Lumacaftor 200
Normalized name: lumacaftor 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 200 mg once daily and ivacaftor 250 mg every 12 h for 14 days followed by 7 days of ivacaftor or 21 days of placebo
Study: 24973281
Drug: Lumacaftor 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 400 mg once daily
Study: 24973281
Drug: Lumacaftor 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 600 mg once daily
Study: 24973281
Drug: Lumacaftor 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor 400 mg every 12 h
Study: 19229449
Drug: Low-frequency repetitive
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency repetitive transcranial magnetic stimulation (0.5 Hz, 15 min/session, twice a day for 2 weeks)
Study: 17373173
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide (BP) 9% cleanser daily, clindamycin 1% foam daily, doxycycline 100 mg twice daily
Study: 17373173
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide (BP) 9% cleanser daily, doxycycline 100 mg twice daily without clindamycin 1% foam
Study: 9592633
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IGF‐I (rhIGF‐I) therapy (40‐80 micrograms/kg/day)
Study: 20019909
Drug: Cadmium exposure
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadmium exposure (measured as blood cadmium concentration of 0.21 microg/L)
Study: 9726716
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with nebulized 2.5 mg salbutamol plus 0.5 mg ipratropium bromide
Study: 9726716
Drug: Nebulized 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 2.5 mg salbutamol alone
Study: 2493044
Drug: Theophylline-terfenadine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline-terfenadine combination
Study: 17611232
Drug: Oral co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-amoxiclav (50 mg/kg/day in three doses for 10 days)
Study: 17611232
Drug: Parenteral ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral ceftriaxone (50 mg/kg/day in a single parenteral dose for three days) followed by oral co-amoxiclav (50 mg/kg/day in three divided doses for seven days)
Study: 17611232
Drug: Parenteral ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral ceftriaxone followed by oral co-amoxiclav
Study: 12162764
Drug: Cisplatin/epinephrine injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/epinephrine injectable gel
Study: 1674853
Drug: Ipsapirone, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipsapirone, 0.3 mg/kg
Study: 6758747
Drug: Sodium Heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Heparin
Study: 28805045
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab at 2 mg/kg
Study: 19630068
Drug: Interpersonal Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Therapy
Study: 19630068
Drug: Cognitive factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive factor estimated cost and treatment
Study: 19630068
Drug: Pre-treatment use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment use of anxiolytics
Study: 17645261
Drug: Combined TCM
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined TCM and western medicine
Study: 16286871
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of whey and caseinate proteins (PROT)
Study: 9862605
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to alternative medication
Study: 2296932
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily oral folic acid supplement (F group)
Study: 6968153
Drug: Anticoagulant or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant or antiplatelet therapy
Study: 6968153
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antithrombotic therapy)
Study: 31055526
Drug: Increased level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased level of blood medium-weight molecules (MWM254)
Study: 31055526
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hypoleptinemia with severe endogenous intoxication
Study: 16365887
Drug: ThermaCool device
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThermaCool device (one treatment)
Study: 16365887
Drug: ThermaCool device
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThermaCool device (two treatments)
Study: 16365887
Drug: ThermaCool device
Approvals — FDA: no, EMA: no, PMDA: no
Description: ThermaCool device (one and two treatments)
Study: 2242492
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection for the first 6 months, followed by sCT 100 MRC U injected i.m. every other day for the next 6 months
Study: 358766
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of lidocaine (bolus dose 50 mg followed by infusion 3 mg/min)
Study: 358766
Drug: QX-572 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: QX-572 (600 mg N,N‐bis dimethylammonium chloride) as an i.v. infusion during 30 min or 60 min
Study: 358766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard lidocaine therapy)
Study: 22499718
Drug: Ginseng (G)
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (G)
Study: 22499718
Drug: Ginseng +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng + Exercise (G+Ex)
Study: 19230172
Drug: cilazapril 10
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 10 mg
Study: 19230172
Drug: cilazapril 5
Normalized name: cilazapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 5 mg
Study: 9931211
Drug: Oxygen via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen via face mask at 12 l/min (group C)
Study: 9931211
Drug: Oxygen via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen via nasal prongs at 5 l/min (group B)
Study: 7844680
Drug: Parenteral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral L-carnitine supplementation (50 mumol/kg per day)
Study: 7844680
Drug: Parenteral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral L-carnitine supplementation
Study: 2190462
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN), 120 mg once daily
Study: 2190462
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg twice daily
Study: 20587541
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UV‐A (25%), UV‐B (5%) and visible light (70%)
Study: 17624203
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, adjusted to 25 mg or 100 mg as needed)
Study: 11228485
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/d for 1 year
Study: 7846210
Drug: Lorazepam (0.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.0, 0.06, 0.13, 0.25, 0.5 mg; total cumulative dose: 0.94 mg)
Study: 26437529
Drug: Aromatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatic therapy using menthol
Study: 21468614
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (500 mg in 20 ml saline)
Study: 21468614
Drug: Levobupivacaine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (100 mg in 20 ml 0.5%)
Study: 21468614
Drug: Lornoxicam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (8 mg in 20 ml saline)
Study: 11123496
Drug: Infusion devices
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion devices prepared by pharmacy (5 days)
Study: 11123496
Drug: Reconstituted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted drugs by patients (5 days)
Study: 29154159
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing therapy (EMDR)
Study: 28760425
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (60 μg/d as selenious acid added to PN)
Study: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg per day
Study: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 400 mg per day
Study: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 800 mg per day
Study: 23731375
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 200 mg per day, 400 mg per day, and 800 mg per day
Study: 16364710
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (PRO, Myoplex, EAS, Inc. Golden CO) containing 280 kcal, 42 g protein, 21 g carbohydrate, and 1.5 g fat
Study: 9457544
Drug: Self-reinforced poly-L-lactide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reinforced poly-L-lactide (SR-PLLA) screws
Study: 6127963
Drug: Intravenous theophyllamine
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophyllamine (maximal mean plasma concentration of 16.7 +/- 1.21 micrograms/ml)
Study: 6127963
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (five inhalations)
Study: 6127963
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (equipotent doses)
Study: 6127963
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (equipotent doses)
Study: 31626158
Drug: Magnetophoretic diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetophoretic diclofenac gel delivery using a traveling magnetic field (intensity, 20 mT; frequency, 6.25 Hz; exposure 20 min, 12 sessions)
Study: 31626158
Drug: Low-frequency pulse
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency pulse magnetotherapy with traveling magnetic field without topical diclofenac therapy
Study: 17686440
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with gemcitabine after first-line therapy
Study: 17686440
Drug: Adding bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adding bevacizumab to standard treatment
Study: 17686440
Drug: Platinum-based doublet
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based doublet with an additional cytotoxic agent
Study: 7696057
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with tracheal tube, neuromuscular blockers
Study: 7696057
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with tracheal tube, no neuromuscular blocker (Group 2)